Your browser doesn't support javascript.
loading
Leiomyoma-like Morphology in Metastatic Uterine Inflammatory Myofibroblastic Tumors.
Devins, Kyle M; Samore, Wesley; Nielsen, G Petur; Deshpande, Vikram; Oliva, Esther.
Affiliation
  • Devins KM; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: kdevins@mgh.harvard.edu.
  • Samore W; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Nielsen GP; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Deshpande V; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Oliva E; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Mod Pathol ; 36(6): 100143, 2023 06.
Article in En | MEDLINE | ID: mdl-36806735
ABSTRACT
Uterine inflammatory myofibroblastic tumors (IMTs) are rare mesenchymal neoplasms that frequently harbor ALK gene rearrangements and have a low risk of metastasis. We reported 3 of these tumors mimicking the appearance of leiomyoma in their recurrence. These patients were 34, 43, and 45 years old. Two uterine tumors demonstrated classic morphology, with combined myxoid, compact fascicular, and hyalinized patterns and spindled cells with bipolar cytoplasmic processes, moderate atypia, and lymphoplasmacytic inflammatory infiltrates. The third had a "leiomyoma-like" appearance, with fascicles of plump spindled cells and a sparse lymphoplasmacytic infiltrate. ALK immunohistochemistry was positive in all the tumors, and all demonstrated ALK rearrangements using fluorescence in situ hybridization (n = 2) and/or RNA sequencing (n = 2). Two classic IMTs recurred at 3 and 50 months in the lung and abdomen, respectively, and recurrent tumors had a "leiomyoma-like" appearance, with 0 and 1 mitosis per 10 high-power fields, no inflammation in 1, and a sparse lymphocytic infiltrate in the other. ALK was positive in both tumors; 1 with available tissue showed an IGFBP5ALK fusion using RNA sequencing. The third patient, who had a "leiomyoma-like" uterine tumor, experienced multiple recurrences, first in the abdomen at 100 months showing a similar appearance. Subsequent recurrence at 105 months showed transmural invasion of the sigmoid colon and a similar microscopic appearance but with the addition of infiltrative borders, moderate cellularity, mild-to-moderate atypia, and 10 mitoses per 10 high-power fields. Both recurrences were positive for ALK, and RNA sequencing revealed the same ACTG2ALK fusion transcript identified in the primary tumor. The patient was treated with crizotinib, resulting in prolonged clinical remission, with no evidence of disease at 168 months from the initial surgery. Although "leiomyoma-like" uterine IMTs have been recently described, to our knowledge, this is the first report of recurrence of these tumors and the first report of a "leiomyoma-like" appearance in the recurrences of conventional uterine IMTs. A low threshold for performing ALK immunohistochemistry on recurrent uterine tumors can identify patients who may benefit from tyrosine kinase inhibitors.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Uterine Neoplasms / Leiomyoma Limits: Female / Humans Language: En Journal: Mod Pathol Journal subject: PATOLOGIA Year: 2023 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Uterine Neoplasms / Leiomyoma Limits: Female / Humans Language: En Journal: Mod Pathol Journal subject: PATOLOGIA Year: 2023 Document type: Article
...